Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Enhertu candidate had been granted priority review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.
Read more
(Alliance News) - Stock trading in London is set for a downbeat return following the long Easter weekend, with traders mulling global growth prospects.
Read more
TOKYO, April 18 (Reuters) - A Japanese Health Ministry committee said on Monday it has approved Novavax Inc's COVID-19 vaccine, setting the stage for full approval of the country's fourth shot for the coronavirus.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday afternoon:
Read moreBRUSSELS, April 14 (Reuters) - Poorer nations have refused tens of millions of AstraZeneca COVID-19 vaccines from the global programme COVAX, a document shows, the latest sign that its short shelf life is sapping demand for the shot.
Read moreApril 12 (Reuters) - The UK's top share index closed down on Tuesday as bearish brokerage calls on companies like Rolls Royce and weakness in defensive sectors offset gains in commodity-linked stocks.
Read more(Sharecast News) - Analysts at Berenberg raised their target price on AstraZeneca shares from £100 to £120 on Tuesday, stating the stock was now "hot to trop".
Read more(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:
Read moreTOKYO, April 11 (Reuters) - Japan has cancelled the purchase of about 40 million Astrazeneca Plc COVID-19 vaccine doses it agreed to buy last year, a health ministry official said in parliament on Monday.
Read moreApril 8 (Reuters) - Britain's top equity index closed at a eight-week high on Friday, lifted by commodity and banking stocks at the end of a volatile week that saw concerns about higher U.S. interest rates and the Ukraine conflict rattle investors.
Read more(Sharecast News) - Analysts at JP Morgan hiker their target price for shares of AstraZeneca and pointed to the potential for "significant" future upward revisions to analysts' estimates for the profitability of the company's oncology pipeline.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:
Read more(Alliance News) - AstraZeneca PLC said on Wednesday new, prolonged follow-up results from the phase three Champion-MG trial showed that Ultomiris demonstrated long-term efficacy in adults with generalised myasthenia gravis.
Read more
Last checked at